RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
  Bladder
  Blood
  Bone Cancer
  Brain
  Breast Cancer
  Carcinogens
  Cervical Cancer
  Colon
  Endometrial
  Esophageal
  Gastric Cancer
  Liver Cancer
  Lung
  Nerve Tissue
  Ovarian Cancer
  Pancreatic Cancer
  Prostate Cancer
  Rectal Cancer
  Renal Cell Carcinoma
  Risk Factors
  Skin
  Testicular Cancer
  Therapy
   Pharmacotherapy
   Radiotherapy
   Vaccination
  Thyroid
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Therapy Channel

subscribe to Therapy newsletter
Latest Research : Cancer : Therapy

   EMAIL   |   PRINT
Mapatumumab :TRAIL receptor 1 Agonistic Human Monoclonal Antibody for Advanced Non-Hodgkin's Lymphoma Reaches Phase 2 Trial

Mar 4, 2005 - 9:37:00 AM
"This therapeutic approach produces cures in approximately fifty percent of patients with aggressive lymphoma. Additional chemotherapeutic and other therapeutic modalities are used to treat non-Hodgkin's lymphoma patients who relapse or do not respond, but cures are difficult to achieve."

 
[RxPG] Human Genome Sciences, Inc.announced today that it has completed the enrollment and initial dosing of patients in a Phase 2 clinical trial of HGS-ETR1 (mapatumumab) in advanced non-Hodgkin's lymphoma.

The Phase 2 clinical trial is a multi-center, open-label study to evaluate the efficacy, safety and tolerability of HGS-ETR1, an agonistic human monoclonal antibody to TRAIL receptor 1, in patients with relapsed or refractory non-Hodgkin's lymphoma.

Patients enrolled in the trial are receiving up to six cycles of treatment in the absence of disease progression, with HGS-ETR1 administered as an intravenous infusion once every twenty-one days.

The objectives of the study are to evaluate disease activity and tumor response to HGS-ETR1 in patients with advanced non-Hodgkin's lymphoma, to evaluate the safety and tolerability of HGS-ETR1, and to determine plasma concentrations of HGS-ETR1 for use in a population pharmacokinetic analysis.

On November 30, 2004, Human Genome Sciences announced the completion of enrollment and initial dosing of patients in a Phase 2 study of HGS-ETR1 in advanced non-small cell lung cancer.On February 23, 2005, the company announced the completion of enrollment and initial dosing of a Phase 2 study of the drug in advanced colorectal cancer.

The three Phase 2 studies of HGS-ETR1 initiated to date fit into a global clinical development program through which Human Genome Sciences is evaluating the novel, genomics-derived anticancer drug's potential for use in the treatment of specific cancers.

Anas Younes, M.D., Professor, Lymphoma/Myeloma, University of Texas M.D. Anderson Cancer Center, Houston, said, "The current standard of care for non- Hodgkin's lymphoma calls for treating most patients with a combination of chemotherapy and, in recent years, monoclonal antibodies. This therapeutic approach produces cures in approximately fifty percent of patients with aggressive lymphoma. Additional chemotherapeutic and other therapeutic modalities are used to treat non-Hodgkin's lymphoma patients who relapse or do not respond, but cures are difficult to achieve. There remains a significant need for new therapies that can improve response rates, extend the duration of response, extend survival, minimize toxicity, and provide patients with improved quality of life. We look forward to continuing the evaluation of HGS-ETR1 to determine whether it may play a role in the treatment of non- Hodgkin's lymphoma."

Gilles Gallant, B. Pharm., Ph.D., Vice President, Clinical Oncology, said, "We are pleased to have completed the enrollment and initial dosing of three Phase 2 studies to evaluate the potential use of HGS-ETR1 as a treatment for specific cancers, including non-small cell lung cancer, colorectal cancer and, now, non-Hodgkin's lymphoma. We have seen a high level of interest in the emerging clinical and preclinical evidence demonstrating that agonistic antibodies to TRAIL receptors 1 and 2 have significant potential to provide novel therapeutic options to patients with a variety of cancer types, including non-Hodgkin's lymphoma.We expect to have the results of all three of the ongoing Phase 2 studies of HGS-ETR1 available in 2005. We also have initiated Phase 1b clinical studies of HGS-ETR1 in combination with chemotherapy. We plan to continue to elucidate the potential of HGS-ETR1 as a treatment for non-Hodgkin's lymphoma and solid tumor malignancies, both as a single agent and in combination with chemotherapeutic agents."

Interim results of two ongoing Phase 1 multi-center, open-label, dose- escalation clinical trials of HGS-ETR1 were presented in September 2004 at the 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Geneva, Switzerland.The data presented demonstrate the safety and tolerability of HGS-ETR1 in patients with advanced solid tumors or non- Hodgkin's lymphoma, and support further evaluation of HGS-ETR1 in Phase 2 clinical trials, both as a single agent and in combination with chemotherapy.

Data were presented on 39 patients treated to date in a Phase 1 study conducted in patients with advanced solid tumors. Interim results of the ongoing study demonstrate that HGS-ETR1 can be administered safely and repetitively to patients with advanced solid malignancies at doses up to and including 10 mg/kg intravenously every 28 days. Some preliminary evidence of biological activity has been observed. Durable stable disease was observed in some patients.

Data also were presented on 24 patients treated to date in an additional Phase 1 study conducted in patients with advanced solid tumors or non-Hodgkin's lymphoma. Results presented from the ongoing clinical trial demonstrate that HGS-ETR1 is well tolerated with no clearly attributable toxicities to date and that the Maximum Tolerated Dose has not been reached. Stable disease has been observed in eight patients for greater than two cycles. The trial continues to enroll patients.

Human Genome Sciences, using genomic techniques, originally identified the TRAIL receptor-1 protein as a member of the tumor necrosis factor receptor super-family. The company's own studies, as well as those conducted by others, show that TRAIL receptor 1 plays a key role in triggering apoptosis, or programmed cell death, in tumors.

Human Genome Sciences took the approach of developing human monoclonal antibodies that would bind the receptor and stimulate the TRAIL receptor-1 protein to trigger apoptosis in cancer cells, in much the same way that the native TRAIL ligand (tumor necrosis factor- related apoptosis-inducing ligand) triggers it, but with the advantage of a longer half-life and an exclusive specificity for TRAIL receptor 1.

The TRAIL receptor 1 agonistic human monoclonal antibody, HGS-ETR1, was made in a collaboration between Human Genome Sciences and Cambridge Antibody Technology. The drug will be produced in the Human Genome Sciences clinical manufacturing facilities located in Rockville, Maryland. Human Genome Sciences holds the commercial rights to the drug.

Non-Hodgkin's lymphoma is the seventh most common cancer in the United States, with approximately 56,000 new cases diagnosed each year.



Publication: Human Genome Sciences, Inc.
On the web: Human Genome Sciences 

Advertise in this space for $10 per month. Contact us today.


Related Therapy News
Taccalonolides from bat plants selectively kill cancer cells
Photodynamic therapy can help preserve the voice for patients with early stage laryngeal cancer
Bionic Nose to Detect Cancers
Anti- cancer gene discovered- new strategy for treatment?
Anthracycline induced heart damage can be reduced by prolonging infusion time
Genomic signatures to guide the use of chemotherapeutics
CDK2/FOXO1 as drug target to Prevent Tumors
Telomerase inhibitors may revolutionize cancer therapy
First ever shots of the cervical cancer vaccine administered in Queensland
Gleevec can be toxic to the heart

Subscribe to Therapy Newsletter

Enter your email address:


 Additional information about the news article
For more information about HGS-ETR1,check the related links .Health professionals interested in more information about trials involving Human Genome Sciences products are requested to inquire via the Contact Us section of the Human Genome Sciences web site,or by calling 301-610-5790, extension 3550.Human Genome Sciences is a company with the mission to treat and cure disease by bringing new gene-based protein and antibody drugs to patients.HGS and Human Genome Sciences are trademarks of Human Genome Sciences, Inc.
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)